F E B R U A R Y 2 5 , 2 0 2 2 Bio-Rad Investor Laboratories, Inc. Day 2022 Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. Some statements in this presentation may be forward-looking st

F E B R U A R Y 2 5 , 2 0 2 2 Bio-Rad Investor Laboratories, Inc. Day 2022

Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. Some

statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management s goals, plans, and expectations, our

future financial performance, our future financial projections, our growth strategy, and other matters. Forward looking statements generally can be identified by the use of forward-looking terminology such as, anticipate,

believe, expect, assume, continue, may, will, intend, estimate, or similar expressions or the negative of those terms or expressions, although not all

forward-looking statements contain these words. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are statements regarding the impact

of the COVID-19 pandemic on Bio-Rad s results and operations. Our actual results may differ materially from these plans and expectations, and the impact and

duration of the COVID-19 pandemic is unknown. Undue reliance should not be placed on these forward-looking statements, and it is encouraged to review our SEC filings, where the risk factors in our business are

discussed in detail. The forward-looking statements contained in this presentation reflect our views and assumptions only as of the date of this presentation. While we may elect to update forward-looking statements at some point in the future, we

specifically disclaim any obligation to do so, even if estimates change, so you should not rely on these forward-looking statements as representing our views as of any date other than the date of this presentation. Use of Non-GAAP Reporting and Currency-Neutral. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain

non-GAAP financial measures, including non-GAAP revenue, non-GAAP gross margin, non-GAAP

adjusted EBITDA, and non-GAAP adjusted EBITDA margin, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset

impairment charges, valuation changes of equity-owned securities, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP revenue, non-GAAP gross margin, non-GAAP adjusted EBITDA, and non-GAAP adjusted EBITDA margin also exclude certain other gains and losses that

are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal

operations and/or, in certain cases, are difficult to forecast accurately for future periods. We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall

performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be

helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for

financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures

provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer

companies. More specifically, management adjusts for the excluded items for the following reasons: Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to

purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to

better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies. Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated

with our acquisitions, such as transaction costs, professional fees for assistance with the transaction; valuation or integration costs; changes in the fair value of contingent consideration, gain or loss on settlement of pre-existing relationships with the acquired entity; or adjustments to purchase price. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business. Restructuring, impairment charges and valuation changes in equity-owned securities and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or

groups of employed assets and charges and benefits arising from valuation changes in equity-owned securities and gains and losses on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary

course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going

operations with prior and future periods. Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We

exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment. From time to time in the future, there may be

other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management. Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each

local currency using the current period s monthly average foreign exchange rates for that currency and comparing that to current period sales. There are limitations in using non-GAAP financial measures

because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial

measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of

this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Non-GAAP adjusted

EBITDA includes an annual dividend from our investment in Sartorius AG. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures

as provided in the tables accompanying this presentation. In addition, for 2020 and 2021 we have presented information about core revenue, which we define as currency neutral non-GAAP revenue and excludes

COVID related sales. We present this core revenue measure since we think it is helpful for understanding the performance of the rest of our business excluding COVID related sales. In 2020 and 2021, COVID related sales were approximately

$318 million and $266 million respectively. COVID related sales for Life Science in 2020 and 2021 were approximately $311 million and $247.1 million respectively, and Covid related sales for Clinical Diagnostics in 2020 and 2021

were approximately $7 million and $18.6 million respectively. Free cash flow is a non-GAAP measure and is defined as cash flow from operations minus net capital expenditures. We believe free cash

flow is a helpful financial metric for use in evaluating the company s financial performance since it measures our ability to generate additional cash from our business operations. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future

acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity -method

investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all. Additional Disclosures. The data included

in this presentation regarding markets and the industry in which we operate, including the size of certain markets, are based on publicly available information and published industry sources. In presenting this information, we have also made certain

estimates and assumptions that we believe to be reasonable based on the information referred to above and similar sources, as well as our internal research, calculations and assumptions based on our analysis of such information and our knowledge of,

and our experience to date in, our industries and markets. Market share data is subject to change and may be limited by the availability of raw data, the voluntary nature of the data gathering process and other limitations inherent in any

statistical survey of market share data. Accordingly, you are cautioned not to place undue reliance on such market share data or any other such estimates. While we believe such information is reliable, we cannot guarantee the accuracy or

completeness of this information.

Today s Program Our Progress, Our Future Lunch Break Norman Schwartz Chief Executive Officer Clinical Diagnostics Dara Wright

Executive Vice President, President, Clinical Diagnostics Group Business Transformation Andy Last Executive Vice President, Chief Operating Officer Finance Update Ilan Daskal Life Science Executive Vice President, Chief Financial Officer Simon May

Executive Vice President, Q&A President, Life Science Group All

Our Progress, Our Future Norman Schwartz Chief Executive Officer

Bio-Rad Today Agenda Progress Since 2017 Advancing Our Continued

Transformation 2025 Goals

Core Values OUR MISSION To provide useful, high-quality products and services that advance scientific discovery and improve healthcare

INVOLVEMENT INTEGRITY INNOVATION INDEPENDENCE

Investment Thesis Well established company with a strong brand and high-quality products Key positions in large,

diversified markets with many opportunities for growth Strong recurring revenue providing for consistency and predictability Healthy balance sheet and strong cash flow for continued investment in our future World-class team

keenly focused on operational excellence

Today s Golden Age of Biology Cell & Gene Therapy 1700+ Cell, Gene & RNA therapy clinical trials in

2021 Demand for precision medicine driving market growth Novel Therapeutics 50+ novel therapeutics approved by FDA in 2021, vs. 16 in 2016 Rising prevalence of medical ailments driving demand for therapeutics Covid Testing

4B+ tests performed globally in 2021 $38B market in 2021, vs. $20B in 2020 Molecular Diagnostics $35B+ market driven by early diagnosis Cancer, infectious diseases and novel technologies driving adoption

Bio-Rad Today Global leader of innovative products in life science research and clinical

diagnostics 70 $2.9B 7,900 Years Strong Annual Sales* Employees Worldwide Performance Continuous Innovation A History of Contribution Key Competencies Fueling Ongoing Growth Complementary Business Segments Leveraging Across the Company

Two Highly Complementary Business Segments Vertically integrated, global commercial platform

Diversified Customer Base & Geographic Profile 70% recurring revenue provides stability and predictability across the business

No single customer accounts for more than 2% of sales

Opportunities Across All Product Areas 80%+ of sales from products in which Bio-Rad has a

leading market position Life Science Gene Expression Protein Quantitation Bioseparation Molecular Biology Cell Biology Clinical Diagnostics Quality Controls Immunohematology Infectious Diseases Diabetes Monitoring Clinical Immunology

Robust Portfolio Spans Continuum of Fast-Growing Markets Bio-Rad technologies are broadly

applicable across multiple growth segments Genomics / Cell Biology / Proteomics / Informatics Discovery Development Production Diagnostics & Monitoring

Our Phase 1 Financial Objectives (2017-2020) Driving Revenue Growth Expanding EBITDA Margins(1)(2) Accelerating Free Cash Flow (1)(3)

Creating Shareholder Value Target Revenue Growth 3 5% Target EBITDA Margins 20%+ in 2020 Grow Faster than EBITDA(1) Deliver Substantial Value A reconciliation of U.S. GAAP results to non-GAAP results

can be found in the Appendix EBITDA Margin defined as Adjusted EBITDA as a percentage of Non-GAAP Revenue Free cash flow is a non-GAAP measure and is defined as cash

flow from operations minus net capital expenditures

Exceeded Our Revenue Targets Driving Revenue Growth Expanding EBITDA Margins Accelerating Free Cash Flow Creating Shareholder Value

Target Revenue(1)(2) Growth 3 5% A reconciliation of U.S. GAAP results to non-GAAP results can be found in the Appendix 2020 and 2021 non-GAAP revenue excludes

payments from legal settlements

Exceeded Our EBITDA Margin Targets Realized operating leverage Driving Revenue Growth Expanding EBITDA Margins Accelerating Free Cash

Flow Creating Shareholder Value Target EBITDA Margins (1)(2) 20%+ in 2020 A reconciliation of U.S. GAAP results to non-GAAP results can be found in the Appendix EBITDA Margin defined as Adjusted EBITDA as a

percentage of Non-GAAP Revenue

Exceeded Our Free Cash Flow Targets Cash flow enables ongoing investment Driving Revenue Growth Expanding EBITDA Margins Accelerating

Free Cash Flow Creating Shareholder Value Grow Faster than EBITDA (1) A reconciliation of U.S. GAAP results to non-GAAP results can be found in the Appendix Free cash flow is a non-GAAP measure and is defined as cash flow from operations minus net capital expenditures

Created Substantial Shareholder Value A result of focus, scale, and operating leverage Driving Revenue Growth Expanding EBITDA Margins

Accelerating Free Cash Flow Creating Shareholder Value Significant Increase in Market Capitalization Source: Refinitiv, Market capitalization at year end for 2017-2021

Advancing Our Continued Transformation A Three Phased Approach Improving financial performance 3 Accelerated 2 Growth

2023 2025 Performance & Operational Mix & market segment focus Operating margin expansion Improvement Channel performance Increase innovation 1 2020 2023 Leverage operational scale

M&A Globalize Portfolio balancing Operations Improving core processes Cost structure improvement 2015 2020 Supply chain transformation Channel excellence Acceleration in Asia SAP

deployment M&A Functionalized organization Standardization

Capital Allocation Priorities Enabling transformation and value creation Reinvest in the business, including R&D and

infrastructure Support accelerated organic growth with strong balance sheet and cash flow Provide optionality for tuck-in or larger-scale acquisitions

Environmental & Social Responsibility Goals Progress on all fronts 2017 Goals for 2030 46% carbon emission reduction 100%

renewable electricity 45% women in U.S. leadership roles 60% of U.S. workforce from under-represented groups 25% reduction of non-recyclable packaging

Enhancing Our Financial Profile Through 2025 Accelerating our revenue growth profile Further improving our cost structure

Expanding profitability Creating shareholder value through prudent capital deployment (1) A reconciliation of U.S. GAAP results to non-GAAP results can be found in the Appendix (2) We

define core revenue as currency neutral non-GAAP revenue and excludes COVID-related sales (3) EBITDA Margin defined as Adjusted EBITDA as a percentage of non-GAAP

Revenue 9% Target (1)(2) Core Revenue CAGR Currency Neutral 28% Target Profitability Adjusted EBITDA Margin (1)(3) 2025

Business Transformation Andy Last Chief Operating Officer

Agenda Transformation Focus & Key Elements Key Growth Drivers COVID Impact Performance Improvement

Phased Corporate Transformation Strategy Improving financial performance & capabilities 3 Accelerated 2 Growth Performance

2023 2025 & Operational Mix & market segment focus Improvement Operating margin expansion Channel performance 1 Increase innovation 2020 2023 Globalize Leverage operational scale

Portfolio balancing M&A Operations Improving core processes Cost structure improvement Supply chain transformation 2015 2020 Channel excellence SAP deployment Acceleration in Asia